Trial Profile
TRK-250 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Inhaled Dose, Safety, Tolerability, and Pharmacokinetic Study of TRK-250 in Subjects With Idiopathic Pulmonary Fibrosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs BNC 1021 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man
- Sponsors Toray Industries
- 24 May 2023 Results assessing the safety, tolerability, and pharmacokinetics of TRK-250 in idiopathic pulmonary fibrosis patients, presented at the 119th International Conference of the American Thoracic Society.
- 15 Jun 2022 Status changed from active, no longer recruiting to completed.
- 21 Feb 2022 Planned End Date changed from 1 Feb 2022 to 1 Mar 2022.